ROVI updates its strategy in a meeting with shareholders, investors and analysts
Mar, 16/11/2021 - 14:31
1 minROVI updates its strategy in a meeting with shareholders, investors and analysts
Relacionados
Los ingresos operativos se situaron en 763,7 millones de euros en 2024, una disminución del 7,9% respecto a 2023 debido principalmente...
20 min
25/02/2025
Al cierre de los nueve primeros meses de 2024
ROVI LOGRA 564,6 MILLONES DE EUROS DE INGRESOS OPERATIVOS E INCREMENTA SU MARGEN BRUTO...
27 min
07/11/2024
Madrid, España - 24 de octubre 2024 – Laboratorios Farmacéuticos Rovi, S.A. (en adelante, “ROVI”), compañía farmacéutica paneuropea...
3 min
24/10/2024
shutterstock_1323088832.jpg
TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)
Madrid, 16 November 2021
In compliance with the reporting requirements provided for in article 227 of the consolidated text of the Securities Market Act, ROVI sends and publishes the attached presentation regarding the update of the company strategy, a presentation that will be distributed today and which can be accessed through the website of the company. Likewise, ROVI will hold a virtual meeting today with analysts and investors to present said presentation.
Mr. Juan López-Belmonte Encina
Chairman and Chief Executive Officer
Laboratorios Farmacéuticos ROVI, S.A.